Results 31 to 40 of about 23,280 (257)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

Frontiers in Pharmacology, 2023
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal ...
Yan Tong, Jian-Qing Huang, Yang Chen, M. Tu, Wei Wang   +4 more
semanticscholar   +1 more source

Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.

European Heart Journal, 2023
AIMS The effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with heart failure (HF) in routine clinical practice is not extensively studied. This study aimed to evaluate the comparative effectiveness of SGLT2i vs. sitagliptin
Edouard L. Fu, E. Patorno, B. Everett, M. Vaduganathan, S. Solomon, R. Levin, S. Schneeweiss, R. Desai   +7 more
semanticscholar   +1 more source

A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

Nature Communications, 2023
This is a phase 1, open-label, single-sequence, multiple-dose, single-center trial conducted in the US (NCT03790839), to evaluate the clinical pharmacokinetics, safety and pharmacodynamics of dorzagliatin co-administered with sitagliptin in patients with
Li Chen, Jiayi Zhang, Yu Sun, Yu Zhao, Xiang Liu, Zhiyin Fang, Lingge Feng, Bin He, Quan-Fei Zou, Gregory J. Tracey   +9 more
semanticscholar   +1 more source

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Diabetes Care, 2020
OBJECTIVE Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.
S. B. Solerte, D, Francesca Addio, R. Trevisan, E. Lovati, A. Rossi, I. Pastore, Dell, Marco Acqua, Elio Ippolito, C. Scaranna, R. Bellante, S. Galliani, A. Dodesini, G. Lepore, Francesca Geni, Roberta Maria Fiorina, E. Catena, A. Corsico, R. Colombo, M. Mirani, C. de Riva, S. Oleandri, R. Abdi, J. Bonventre, S. Rusconi, F. Folli, A. Di Sabatino, G. Zuccotti, M. Galli, P. Fiorina   +30 more
semanticscholar   +1 more source

Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor. [PDF]

PLoS ONE, 2015
Sitagliptin (SG) increases serum GLP-1 (Glucagon-like peptide-1) through inhibition of the hormone degradation. Resistant starch (RS) induces GLP-1 expression by stimulating L-cells in the intestine.
Felicia Goldsmith, Michael J Keenan, Anne M Raggio, Xin Ye, Zheng Hao, Holiday Durham, James Geaghan, Weiping Jia, Roy J Martin, Jianping Ye   +9 more
doaj   +1 more source

The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population

Cureus, 2023
Introduction Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder affecting millions of individuals worldwide. Effective management of T2DM is crucial to prevent complications.
Rana Bhattacharjee, Madhukar Rai, Priyanka Joshi, Ashish Prasad, Ashish Birla   +4 more
semanticscholar   +1 more source

SITAGLIPTIN; SITAGLIPTIN AS ADD ON THERAPY TO PATIENTS ON INSULIN.

The Professional Medical Journal, 2017
The objective of this stidy is to compare the mean reduction of HbA1c in patientstaking sitagliptin insulin combination with insulin alone in patients of type II Diabetes mellitus.Study Design: Randomized control trial (RCT). Setting: Medicine Department, Allied Hospital,Faisalabad. Period: August 2013 to February 2014.
Zaheer Ahmed, Hassan Fareed, Muhammad Usman Musharraf   +2 more
openaire   +2 more sources

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19

Pharmaceuticals, 2022
Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin.
H. Al-kuraishy, A. Al-Gareeb, Sarah M. Albogami, Sabatier Jean-Marc, E. Nadwa, Amin A. Hafiz, W. Negm, M. Kamal, Mohammed Al-Jouboury, E. Elekhnawy, G. Batiha, M. De Waard   +11 more
semanticscholar   +1 more source

Sitagliptin and other ‘gliptins’ - why prescribe them? [PDF]

, 2016
Introduction\ud \ud In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 inhibitors (‘gliptins’).
Dimmitt, Simon B., Doggrell, Sheila
core   +1 more source

Attenuation of acrylamide-induced neurotoxicity by supplementation of sitagliptin in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Acrylamide (ACR) induces neurotoxicity in humans and animals through different mechanisms. Sitagliptin is a type-2 diabetes medication with neuroprotective properties.
Mahboobeh Navabi, Mahboobeh Ghasemzadeh Rahbardar, Soghra Mehri, Hossein Hosseinzadeh   +3 more
doaj   +1 more source